Pre-demographic dividend vs Rwanda: Access to anti-retroviral drugs, male
Pre-demographic dividend
80.4%
in 2024
Rwanda
95.0%
in 2024
Pre-demographic dividend rank
5th
Rwanda rank
4th
Access to anti-retroviral drugs, male over time
- Pre-demographic dividend
- Rwanda
How they compare
Rwanda currently reports 95.0% against 80.4% in Pre-demographic dividend, a difference of 14.6%.
That makes Rwanda's figure about 1.2 times Pre-demographic dividend's.
The two have swapped places 1 time across 25 shared years of data; in 2000 it was Pre-demographic dividend ahead.
Pre-demographic dividend ranks 5th and Rwanda ranks 4th of 19 groups.
Rwanda has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Pre-demographic dividend | Rwanda | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 5.7% | 10.4% | 4.7% | Rwanda |
| 2010s | 37.6% | 60.0% | 22.4% | Rwanda |
| 2020s | 71.5% | 90.0% | 18.5% | Rwanda |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, male, Pre-demographic dividend or Rwanda?
- Rwanda, at 95.0% against 80.4% in Pre-demographic dividend as of 2024.
- What is the difference in access to anti-retroviral drugs, male between Pre-demographic dividend and Rwanda?
- 14.6%, with Rwanda ahead.
- How many years of comparable data are there for Pre-demographic dividend and Rwanda?
- 25 years are reported by both, from 2000 to 2024.
- How do Pre-demographic dividend and Rwanda rank globally for access to anti-retroviral drugs, male?
- Pre-demographic dividend ranks 5th and Rwanda ranks 4th of 19 groups.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, male (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult males living with HIV who are receiving antiretroviral therapy.